To evaluate changes in the integration of Molecular Tumor Boards (MTBs) in neuro-oncology in Germany since the initial 2022 survey, identify persistent gaps, and explore the adoption of digital tools and structural innovations, particularly in light of developments up to 2025.
Key Findings:
74% of participants had access to in-house MTBs, with 20% referring patients to external centers, indicating a trend towards centralized care.
91% of respondents worked in DKG-certified neuro-oncology centers, an increase from 71% in 2022, reflecting improved standards.
The majority of respondents were experienced specialists, primarily in neurosurgery and neurology, which may influence the findings.
Interpretation:
The survey indicates a growing integration of MTBs in neuro-oncology, with increased certification and access; however, challenges remain in standardization, therapy access, and the need for improved integration of MTB recommendations into clinical practice.
Limitations:
Low response rate of approximately 8%, which may limit the representativeness of the findings and introduce potential biases.
Descriptive nature of the longitudinal comparison due to anonymous responses, making it difficult to track changes at the individual level.
Conclusion:
The follow-up survey highlights progress in the integration of MTBs in neuro-oncology while underscoring the need for continued efforts to address barriers and enhance precision medicine practices.
